Oragon150 mg

Oragon is a gonadotropin-releasing hormone (GnRH) receptor antagonist that is FDA-approved for the following use:

• Moderate to severe pain associated with endometriosis in women of reproductive age - this is the established, approved indication supported by robust clinical trial evidence.

Oragon is not indicated for use in postmenopausal women, in men, or in children. It is not a contraceptive and does not treat infertility. Use for indications outside the approved label is not supported by adequate evidence and is not recommended.

Each film-coated tablet contains Elagolix Sodium equivalent to elagolix 150 mg or 200 mg (strength as specified on the pack), along with pharmaceutically acceptable excipients.

Oragon is an orally active, non-peptide small-molecule antagonist of the gonadotropin-releasing hormone (GnRH) receptor. It belongs to a newer class of hormonal agents used to suppress ovarian estrogen and progesterone production in a dose-dependent manner, thereby reducing pain associated with endometriosis.

Unlike GnRH agonists, Oragon does not cause an initial hormonal flare and its effect on ovarian hormone suppression is reversible and dose-adjustable, which allows a partial (rather than complete) suppression strategy intended to balance symptom relief against bone density loss.

Oragon belongs to the therapeutic class of Gonadotropin-Releasing Hormone (GnRH) receptor antagonists, used in the hormonal management of endometriosis-associated pain.

Mechanism of Action

Elagolix Sodium works as a competitive antagonist at pituitary GnRH receptors. By blocking these receptors, it suppresses the pulsatile release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn reduces ovarian production of estradiol and progesterone in a dose-dependent fashion.

Pharmacokinetics

• Absorption: Rapidly absorbed after oral administration; food delays and reduces peak concentration.
• Metabolism: Primarily hepatic, via CYP3A4 with minor contributions from CYP2D6 and other pathways; also a substrate/inhibitor of transporters including OATP1B1.
• Elimination: Mainly excreted via feces, with a small renal component; elimination half-life is approximately 4-6 hours.

Oragon is administered orally as a tablet, swallowed whole with water, at a consistent time each day, with or without food. Missed doses should not be doubled; the next dose should be taken at the regular scheduled time. Pregnancy should be excluded before starting treatment, and a barrier or non-hormonal method of contraception should be used throughout therapy.

Oragon has several clinically significant drug interactions:

• Strong OATP1B1 inhibitors (e.g., cyclosporine, gemfibrozil): significantly increase plasma concentrations of Oragon and are contraindicated in combination (see Contraindications).
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase exposure to Oragon; concurrent use requires dose/duration limitation (200 mg twice daily limited to under 1 month; 150 mg once daily limited to 6 months).
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John's Wort): reduce efficacy of Oragon; the 200 mg twice-daily regimen should be avoided, and the 150 mg once-daily regimen limited to 6 months.
• Estrogen-containing hormonal contraceptives: may reduce the effectiveness of Oragon and are not recommended during treatment; combination has also been shown to substantially raise estrogen exposure.

Common side effects of Oragon include:

• Hot flashes / night sweats
• Headache
• Nausea
• Insomnia and other sleep disturbances
• Amenorrhea (absence of menstrual periods)
• Mood changes, anxiety, or new/worsening depression (see Precautions and Warnings)
• Arthralgia (joint pain)
• Elevations in liver enzymes and changes in lipid profile (cholesterol, LDL, HDL, triglycerides)

Patients should promptly report severe mood changes, suicidal thoughts, yellowing of skin/eyes, or signs of an allergic reaction while taking Oragon.

Pregnancy

Oragon is contraindicated in pregnancy. Exposure early in pregnancy may increase the risk of early pregnancy loss. Pregnancy should be excluded before starting treatment, and a non-hormonal method of contraception should be used during therapy and for at least 28 days afterward. If pregnancy occurs during treatment, Oragon should be discontinued immediately and the patient should consult her physician.

Lactation

There is no adequate human data on the presence of Oragon in breast milk or its effects on the breastfed infant or on milk production. Oragon should be used during breastfeeding only if clearly needed and the potential benefit justifies the potential risk to the infant; a physician should be consulted before use while breastfeeding.

Bone Mineral Density Loss

Oragon causes dose- and duration-dependent decreases in bone mineral density, which may not be fully reversible after stopping treatment. Treatment duration should be limited according to dose, and bone density assessment should be considered for women with additional osteoporosis risk factors or with prolonged use.

Hepatic Effects

Dose-dependent elevations in liver enzymes (ALT) have been observed. Oragon is contraindicated in severe hepatic impairment and dose/duration must be limited in moderate hepatic impairment.

Mood Changes

New or worsening depression, anxiety, mood changes, and rare reports of suicidal ideation have occurred with Oragon. Patients and caregivers should be counseled to seek prompt medical attention for any new or worsening mood symptoms.

Lipid Changes

Dose-dependent increases in total cholesterol, LDL, HDL, and triglycerides have been reported; monitoring may be appropriate in patients with pre-existing lipid disorders.

Contraception

Oragon is not a contraceptive. Use non-hormonal contraception during treatment and for at least 28 days after stopping, as estrogen-containing methods may reduce its effectiveness.

There is limited clinical experience with overdose of Oragon. In the event of a suspected overdose, seek immediate medical attention or contact a poison control center. Management should be supportive and symptomatic, with monitoring of vital signs and relevant laboratory parameters as directed by a physician; there is no specific antidote.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal Impairment

No dose adjustment of Oragon is required in patients with renal impairment; however, it has not been specifically studied in severe renal impairment or end-stage renal disease.

Hepatic Impairment

Dose and duration must be limited in moderate hepatic impairment (150 mg once daily, up to 6 months); Oragon is contraindicated in severe hepatic impairment (see Contraindications).

Elderly / Postmenopausal Women

Oragon is not indicated for use in postmenopausal women.

Pediatric Population

Safety and efficacy of Oragon have not been established in pediatric patients (see Pediatric Use).

Treatment duration with Oragon is dose-dependent because of the risk of bone mineral density loss:

• 150 mg once daily: up to 24 months.
• 200 mg twice daily: up to 6 months.
• 150 mg once daily with moderate hepatic impairment or concurrent strong CYP3A4 inhibitors: up to 6 months.
• 200 mg twice daily with concurrent strong CYP3A4 inhibitors: less than 1 month.

The lowest effective dose for the shortest duration necessary should be used, per physician guidance.

Elagolix Sodium belongs to the drug class of oral gonadotropin-releasing hormone (GnRH) receptor antagonists, a non-peptide, small-molecule hormonal therapy class used for endometriosis-associated pain.

Elagolix Sodium acts as a competitive antagonist at the pituitary GnRH receptor. This blocks endogenous GnRH from stimulating the receptor, leading to dose-dependent suppression of LH and FSH secretion, which reduces ovarian estradiol and progesterone production. This partial, adjustable suppression of ovarian hormones underlies the reduction in endometriosis-associated pain while aiming to limit hypoestrogenic side effects such as bone loss.

The safety and efficacy of Oragon have not been established in pediatric patients. Oragon is not approved for use in children or adolescents, and its use in this population is not recommended outside of a physician's specific guidance in a clinical context where benefit clearly outweighs risk.